Gallium Dotatate for Pancreatic Neuroendocrine Tumors (NETs)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pancreatic Neuroendocrine Tumors (NETs)+1 MoreGallium Dotatate - Drug
Eligibility
19 - 100
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if using a PET/CT scan with NETSPOT can more accurately find neuroendocrine tumors, making it easier to remove them during surgery.

Eligible Conditions
  • Pancreatic Neuroendocrine Tumors (NETs)
  • Carcinoid Syndrome

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: From baseline through 12 months

Month 12
Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement
Week 3
Comparison of intraoperative findings to preoperative PET scan findings

Trial Safety

Trial Design

1 Treatment Group

Gallium Dotatate
1 of 1

Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: Gallium Dotatate · No Placebo Group · Phase < 1

Gallium Dotatate
Drug
Experimental Group · 1 Intervention: Gallium Dotatate · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from baseline through 12 months

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,435 Previous Clinical Trials
2,229,222 Total Patients Enrolled
Sushanth Reddy, MDPrincipal Investigator - University of Alabama at Birmingham
Birmingham VA Medical Center
University Of Alabama School Of Medicine (Medical School)
University Of Ky A B Chandler (Residency)

Eligibility Criteria

Age 19 - 100 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are mentally competent to provide informed consent to participate in the study.
You have a tumor with a pre-operative 68Gallium-DOTATATE scan.
You must be at least 19 years of age to participate in this study